Spots Global Cancer Trial Database for myelofibrosis (mf)
Every month we try and update this database with for myelofibrosis (mf) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04454658 | Myelofibrosis (... | ABBV-744 Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03755518 | Primary Myelofi... Post-Polycythem... Myelofibrosis Post-essential ... | FEDRATINIB | 18 Years - | Celgene | |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | NCT04472598 | Myelofibrosis (... | Navitoclax Ruxolitinib Placebo for Nav... | 18 Years - | AbbVie | |
| Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms | NCT01816256 | Myeloproliferat... Polycythemia Ve... Essential Throm... Myelofibrosis (... | Upper gastroint... | - | University Health Network, Toronto | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | NCT02712905 | Solid Tumors an... | INCB059872 all-trans retin... azacitidine nivolumab | 18 Years - | Incyte Corporation | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders | NCT01224496 | Myelodysplastic... Aplastic Anaemi... Myelofibrosis (... Thalassemia Int... | Chinese herbal ... | 13 Years - 85 Years | Singapore General Hospital | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). | NCT05927012 | Iron Deficiency... | KER-047 | 18 Years - | Keros Therapeutics, Inc. | |
| Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders | NCT01224496 | Myelodysplastic... Aplastic Anaemi... Myelofibrosis (... Thalassemia Int... | Chinese herbal ... | 13 Years - 85 Years | Singapore General Hospital | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
